Search Results - "Forte, Vittorio"

  • Showing 1 - 13 results of 13
Refine Results
  1. 1

    Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss by Masini, Silvia, Bs, Ticconi, Carlo, M.D, Gravina, Paolo, Ph.D, Tomassini, Monica, M.D, Pietropolli, Adalgisa, M.D, Forte, Vittorio, M.D, Federici, Giorgio, M.D, Piccione, Emilio, M.D, Bernardini, Sergio, M.D., Ph.D

    Published in Fertility and sterility (01-08-2009)
    “…Objective To investigate the possible association between selected thrombin-activatable fibrinolysis inhibitor (TAFI) single nucleotide polymorphisms (SNPs)…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes by Ciccacci, Cinzia, Rufini, Sara, Politi, Cristina, Novelli, Giuseppe, Forte, Vittorio, Borgiani, Paola

    Published in Thrombosis research (01-08-2015)
    “…Abstract MicroRNAs are small single stranded molecules that play a crucial role in regulation of physiological and pathological processes. Recent studies…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population by Borgiani, Paola, Ciccacci, Cinzia, Forte, Vittorio, Sirianni, Elisabetta, Novelli, Lucia, Bramanti, Placido, Novelli, Giuseppe

    Published in Pharmacogenomics (01-02-2009)
    “…It is known that warfarin treatment is problematic, due to its narrow therapeutic range and to the great interindividual variability. Numerous papers have…”
    Get more information
    Journal Article
  7. 7

    Resequencing of VKORC1 , CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses by Di Fusco, Davide, Ciccacci, Cinzia, Rufini, Sara, Forte, Vittorio, Novelli, Giuseppe, Borgiani, Paola

    Published in Thrombosis research (01-07-2013)
    “…Abstract Purpose The aim of the present study was to investigate the genetic variability of VKORC1 , CYP2C9 and CYP4F2 genes in patients who required a very…”
    Get full text
    Journal Article
  8. 8

    Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians by Borgiani, Paola, Ciccacci, Cinzia, Forte, Vittorio, Romano, Silvia, Federici, Giorgio, Novelli, Giuseppe

    Published in Pharmacogenomics (01-11-2007)
    “…Warfarin is currently considered to be the anticoagulant of choice in the long-term treatment and prevention of thromboembolic events. However, it presents a…”
    Get more information
    Journal Article
  9. 9
  10. 10

    Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient by Ciccacci, Cinzia, Falconi, Mattia, Paolillo, Nicoletta, Oteri, Francesco, Forte, Vittorio, Novelli, Giuseppe, Desideri, Alessandro, Borgiani, Paola

    Published in Pharmacogenetics and genomics (01-06-2011)
    “…Warfarin (coumadin) is a worldwide-prescribed anticoagulant for the long-term treatment and prevention of thromboembolic events, presenting a great…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13

    Multidimensional Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Venditti, Adriano, Maurillo, Luca, Buccisano, Francesco, Tamburini, Anna, Del Poeta, Giovanni, Ilaria Del Principe, Maria, Panetta, Paola, Irno Consalvo, Maria, Mazzone, Carla, Tendas, Andrea, Trawinska, Margherita, Forte, Vittorio, Amadori, Sergio

    Published in Leukemia & lymphoma (01-01-2003)
    “…The term minimal residual disease (MRD) describes the situation in which, after chemotherapy for acute leukemia (AL), a morphologically normal bone marrow (BM)…”
    Get full text
    Journal Article